MicuRx
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
950 Tower Ln Ste 390, Foster City, Calif...Phone Number
(510) 782-2022Website
www.micurx.comRevenue
$10.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About MicuRx
MicuRx Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the design, discovery, and development of innovative medicines for infectious diseases and unmet medical needs, particularly targeting drug-resistant bacterial infections. Founded in 2007 and headquartered in Shanghai, with branches in California, Hong Kong, and Beijing, the company aims to create the next generation of safe and effective antibiotics. MicuRx is committed to addressing unmet clinical needs through its robust research and development pipeline. The company actively engages in clinical trials and research studies to advance its therapeutic offerings.Explore more
MicuRx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MicuRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if MicuRx is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at MicuRx
Website visits: Recent activity has been detected on your website
Check if MicuRx has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once MicuRx has new funding data
Click to see if MicuRx had a recent Job posting/layoffs
MicuRx, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on MicuRx recently announced quarterly report
Product Launch: Get notified when MicuRx launches new products
Recommended Actions
Reach out to Masked Content who joined MicuRx as Masked Content
Find 3 more new buyers
Compare Similar Companies to MicuRx
Compare insights from companies similar to MicuRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MicuRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MicuRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MicuRx.
MicuRx financials insights
Gather financial insights about MicuRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$10M
2013
Series B
$25M
2016
Series C
$55M
2017
Series D
$15.1M
2020
Other Financing Round
$7.8M
Series E
$107M
MicuRx Tech Stack
A closer look at the technologies used by MicuRx
See more technologies
Most Recent Scoops
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Person-Based
Project
Product Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Product Development, Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
MicuRx News & Media
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", Stock Code: 688373)MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued progression as planned MRX-4 Injection followed by Contezolid Tablets demonstrated favorable safety and efficacy profiles in patients with...MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australia, a self-developed oral antibacterial agent in development for the treatment of...MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MicuRx
Sign Up For FreeTo access detailed company insights
MicuRx Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the design, discovery, and development of innovative medicines for infectious diseases and unmet medical needs, particularly targeting drug-resistant bacterial infections. Founded in 2007 and headquartered in Shanghai, with branches in California, Hong Kong, and Beijing,... Read More
